['cystic fibrosis']
['glpg2222 150 mg q.d.', 'glpg2222 300 mg q.d.', 'placebo']

        Inclusion Criteria:

          1. Male or female subject ≥ 18 years of age, on the day of signing the Informed Consent
             Form (ICF).

          2. A confirmed clinical diagnosis of CF.

          3. One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation
             (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or
             S549R) on the 2nd allele in the CFTR gene (documented in the subject's medical record
             or CF registry).

          4. Weight ≥ 40 kg.

          5. Stable concomitant treatment for at least 4 weeks (28 days) prior to baseline
             (including physician prescribed ivacaftor (Kalydeco®) 150 mg b.i.d.).

          6. Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted normal for age, gender
             and height at screening (pre- or postbronchodilator).

        Exclusion Criteria:

          1. History of clinically meaningful unstable or uncontrolled chronic disease that makes
             the subject unsuitable for inclusion in the study in the opinion of the investigator.

          2. Unstable pulmonary status or respiratory tract infection (including rhinosinusitis)
             requiring a change in therapy within 4 weeks of baseline.

          3. Need for supplemental oxygen during the day, and >2 liters per minute (LPM) while
             sleeping.

          4. History of hepatic cirrhosis with portal hypertension (e.g., signs/symptoms of
             splenomegaly, esophageal varices, etc).

          5. Abnormal liver function test at screening; defined as aspartate aminotransferase (AST)
             and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or total
             bilirubin (>1.5 times ULN (CTCAE Grade 2) and/or gamma-glutamyl transferase (GGT) ≥ 3x
             the upper limit of normal (ULN), and/or total bilirubin (>1.5 times ULN (CTCAE Grade
             2).

          6. Estimated creatinine clearance < 60mL/min using the Cockroft-Gault formula at
             screening.
      